Sanofi (SNY) DCF Valuation

Valoración de DCF Sanofi (SNY)

FR | Healthcare | Drug Manufacturers - General | NASDAQ
Sanofi (SNY) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Sanofi (SNY) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

¡Agilice su análisis y mejore la precisión con nuestra calculadora DCF (SNY)! Utilizando datos reales de Sanofi y supuestos personalizables, esta herramienta le permite pronosticar, analizar y evaluar (SNY) como si fuera un inversor experimentado.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 39,244.7 38,971.5 40,855.0 47,335.4 48,007.0 50,577.5 53,285.7 56,138.8 59,144.7 62,311.6
Revenue Growth, % 0 -0.69623 4.83 15.86 1.42 5.35 5.35 5.35 5.35 5.35
EBITDA 7,415.9 18,264.0 11,775.2 14,665.0 12,511.5 15,337.8 16,159.0 17,024.3 17,935.8 18,896.2
EBITDA, % 18.9 46.87 28.82 30.98 26.06 30.33 30.33 30.33 30.33 30.33
Depreciation 3,905.6 3,412.3 3,265.3 3,857.6 3,937.9 4,355.0 4,588.2 4,833.8 5,092.7 5,365.3
Depreciation, % 9.95 8.76 7.99 8.15 8.2 8.61 8.61 8.61 8.61 8.61
EBIT 3,510.3 14,851.7 8,509.9 10,807.4 8,573.5 10,982.8 11,570.9 12,190.4 12,843.1 13,530.8
EBIT, % 8.94 38.11 20.83 22.83 17.86 21.71 21.71 21.71 21.71 21.71
Total Cash 10,159.8 14,511.7 10,531.0 13,282.2 9,083.5 13,745.2 14,481.2 15,256.6 16,073.5 16,934.1
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 10,515.4 10,379.8 10,206.7 11,206.8 11,513.4
Account Receivables, % 26.79 26.63 24.98 23.68 23.98
Inventories 8,336.8 8,710.2 9,088.7 9,344.2 10,080.5 10,780.9 11,358.2 11,966.3 12,607.0 13,282.1
Inventories, % 21.24 22.35 22.25 19.74 21 21.32 21.32 21.32 21.32 21.32
Accounts Payable 5,540.8 5,522.1 6,445.0 7,105.2 7,642.2 7,585.9 7,992.1 8,420.0 8,870.9 9,345.8
Accounts Payable, % 14.12 14.17 15.78 15.01 15.92 15 15 15 15 15
Capital Expenditure -1,893.9 -2,204.7 -2,130.6 -2,295.4 -3,153.7 -2,743.0 -2,889.8 -3,044.6 -3,207.6 -3,379.3
Capital Expenditure, % -4.83 -5.66 -5.22 -4.85 -6.57 -5.42 -5.42 -5.42 -5.42 -5.42
Tax Rate, % 24.51 24.51 24.51 24.51 24.51 24.51 24.51 24.51 24.51 24.51
EBITAT 3,490.4 13,227.1 6,791.1 8,624.3 6,472.4 9,304.4 9,802.6 10,327.5 10,880.4 11,463.0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -7,809.2 14,178.2 8,643.3 9,591.0 6,750.9 8,920.5 10,647.0 11,217.1 11,817.7 12,450.5
WACC, % 6.4 6.25 6.12 6.12 6.06 6.19 6.19 6.19 6.19 6.19
PV UFCF
SUM PV UFCF 45,728.1
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 12,700
Terminal Value 303,272
Present Terminal Value 224,629
Enterprise Value 270,357
Net Debt 10,128
Equity Value 260,228
Diluted Shares Outstanding, MM 1,256
Equity Value Per Share 207.12

What You Will Receive

  • Comprehensive Financial Model: Sanofi’s actual data provides accurate DCF valuation.
  • Complete Forecast Control: Modify revenue growth, profit margins, WACC, and other essential factors.
  • Real-Time Calculations: Automatic updates allow you to see results instantly as adjustments are made.
  • Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
  • Flexible and Reusable: Designed for adaptability, enabling repeated use for in-depth forecasts.

Key Features

  • Comprehensive SNY Data: Pre-loaded with Sanofi’s historical financial performance and future outlook projections.
  • Customizable Assumptions: Modify revenue growth rates, profit margins, WACC, tax implications, and capital investments.
  • Interactive Valuation Model: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on your adjustments.
  • Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation possibilities.
  • User-Centric Interface: Intuitive, organized, and suitable for both seasoned professionals and newcomers.

How It Works

  1. Download the Template: Gain immediate access to the Excel-based SNY DCF Calculator.
  2. Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
  3. Instant Calculations: The model automatically recalculates Sanofi’s intrinsic value.
  4. Test Scenarios: Explore various assumptions to assess potential changes in valuation.
  5. Analyze and Decide: Utilize the findings to inform your investment or financial strategies.

Why Choose This Calculator for Sanofi (SNY)?

  • Designed for Experts: A sophisticated tool utilized by financial analysts, CFOs, and industry consultants.
  • Accurate Financial Data: Sanofi’s historical and projected financials are preloaded for precise analysis.
  • Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
  • Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential financial metrics.
  • User-Friendly: Step-by-step guidance simplifies the calculation process.

Who Should Use This Product?

  • Individual Investors: Make informed decisions about buying or selling Sanofi (SNY) stock.
  • Financial Analysts: Streamline valuation processes with ready-to-use financial models for Sanofi (SNY).
  • Consultants: Deliver professional valuation insights on Sanofi (SNY) to clients quickly and accurately.
  • Business Owners: Understand how large companies like Sanofi (SNY) are valued to guide your own strategy.
  • Finance Students: Learn valuation techniques using real-world data and scenarios related to Sanofi (SNY).

What the Template Contains

  • Preloaded SNY Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.

No products were found matching.